Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 61 to 75 of 123 results for nivolumab

  1. Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

    Discontinued [GID-TA10221]

    Technology appraisal guidance
    Discontinued

  2. Cabozantinib for untreated advanced renal cell carcinoma (TA542)

    Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA542

  3. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued [GID-TA10495]

    Technology appraisal guidance
    Discontinued

  5. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued [GID-TA10443]

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued [GID-TA10321]

    Technology appraisal guidance
    Discontinued

  7. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  8. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued [GID-TA10590]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued [GID-TA10158]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued [GID-TA10492]

    Technology appraisal guidance
    Discontinued

  12. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued [GID-TA10490]

    Technology appraisal guidance
    Discontinued

  13. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

    Technology appraisal guidance
    Discontinued

  14. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued [GID-TA10233]

    Technology appraisal guidance
    Discontinued

  15. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

    Technology appraisal guidance
    Discontinued